{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:42:10Z","timestamp":1773286930393,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T00:00:00Z","timestamp":1352160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T00:00:00Z","timestamp":1352160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1038\/leu.2012.305","type":"journal-article","created":{"date-parts":[[2012,11,7]],"date-time":"2012-11-07T15:20:36Z","timestamp":1352301636000},"page":"907-913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance\/intolerance"],"prefix":"10.1038","volume":"27","author":[{"given":"E","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P D","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K N","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R A","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O G","family":"Ottmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J P","family":"Radich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D-W","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R C","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,6]]},"reference":[{"key":"BFleu2012305_CR1","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1002\/cncr.22661","volume":"109","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Cortes JE, Giles FJ, O\u2019Brien S, Kantarjian HM . Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007; 109: 2171\u20132181.","journal-title":"Cancer"},{"key":"BFleu2012305_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645\u2013652.","journal-title":"N Engl J Med"},{"key":"BFleu2012305_CR3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu2012305_CR4","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","volume":"11","author":"J Cortes","year":"2005","unstructured":"Cortes J, Talpaz M, O\u2019Brien S, Jones D, Luthra R, Shan J et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005; 11: 3425\u20133432.","journal-title":"Clin Cancer Res"},{"key":"BFleu2012305_CR5","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","volume":"108","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006; 108: 1835\u20131840.","journal-title":"Blood"},{"key":"BFleu2012305_CR6","first-page":"1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Ann Meeting Abstracts 2009; 114: 1126.","journal-title":"ASH Ann Meeting Abstracts"},{"issue":"1","key":"BFleu2012305_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1182\/asheducation-2005.1.183","volume":"2005","author":"N. P. Shah","year":"2005","unstructured":"Shah NP . Loss of response to imatinib: mechanisms and management. Hematol Am Soc Hematol Educ Program 2005, 183\u2013187.","journal-title":"Hematology"},{"key":"BFleu2012305_CR8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.hoc.2004.03.001","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, Hughes T . Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004; 18: 641\u2013656,, ix.","journal-title":"Hematol Oncol Clin North Am"},{"key":"BFleu2012305_CR9","unstructured":"Tasigna (nilotinib) prescribing information Novartis Pharmaceuticals Corporation: East Hanover, NJ, 2012."},{"key":"BFleu2012305_CR10","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540\u20133546.","journal-title":"Blood"},{"key":"BFleu2012305_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz JA, Larson RA, Gattermann N et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood 2011; 117: 1141\u20131145.","journal-title":"Blood"},{"key":"BFleu2012305_CR12","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041\u20136051.","journal-title":"J Clin Oncol"},{"key":"BFleu2012305_CR13","first-page":"2177","volume":"8","author":"HM Kantarjian","year":"2002","unstructured":"Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002; 8: 2177\u20132187.","journal-title":"Clin Cancer Res"},{"key":"BFleu2012305_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008; 112: 516\u2013518.","journal-title":"Blood"},{"key":"BFleu2012305_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3324\/haematol.2009.012781","volume":"95","author":"D Milojkovic","year":"2010","unstructured":"Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010; 95: 224\u2013231.","journal-title":"Haematologica"},{"key":"BFleu2012305_CR16","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"1","author":"JR Anderson","year":"1983","unstructured":"Anderson JR, Cain KC, Gelber RD . Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710\u2013719.","journal-title":"J Clin Oncol"},{"key":"BFleu2012305_CR17","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","volume":"26","author":"JR Anderson","year":"2008","unstructured":"Anderson JR, Cain KC, Gelber RD . Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008; 26: 3913\u20133915.","journal-title":"J Clin Oncol"},{"key":"BFleu2012305_CR18","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO;2-V","volume":"15","author":"M Buyse","year":"1996","unstructured":"Buyse M, Piedbois P . On the relationship between response to treatment and survival time. Stat Med 1996; 15: 2797\u20132812.","journal-title":"Stat Med"},{"key":"BFleu2012305_CR19","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1182\/blood-2010-07-293977","volume":"117","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Kantarjian H, O\u2019Brien S, Shan J, Garcia-Manero G, Wierda W et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 2011; 117: 1822\u20131827.","journal-title":"Blood"},{"key":"BFleu2012305_CR20","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","volume":"114","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Jones D, Kantarjian HM, O\u2019Brien S, Tam C, Koller C et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009; 114: 2037\u20132043.","journal-title":"Blood"},{"key":"BFleu2012305_CR21","first-page":"3296","volume":"114","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Bahceci E, Zhu C, Lambert A, Cortes J . Predictors of long-term cytogenetic response following dasatinib therapy of patients with chronic-phase chronic myeloid leukemia (CML-CP). ASH Ann Meeting Abstracts 2009; 114: 3296.","journal-title":"ASH Ann Meeting Abstracts"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2012305.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012305","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012305.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:05:51Z","timestamp":1648739151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2012305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,6]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["BFleu2012305"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.305","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,6]]},"assertion":[{"value":"17 August 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EJ received honoraria from Novartis and BMS. PDlC acted as a consultant and received honoraria for Novartis and BMS and received research funding from Novartis. JEC acted as a consultant for Novartis, BMS and Pfizer and received research funding from Novartis, BMS, Pfizer, Ariad and Chemgenex. FJG acted as a consultant, received honoraria and research funding from Novartis. KNB received honoraria and research funding from Novartis. JP-I acted as a consultant for Novartis and BMS and received honoraria from Novartis. RAL acted as a consultant, received honoraria, and received research funding from Novartis. NG received honoraria and research funding from Novartis. OGO acted as a consultant, received honoraria, and research funding from Novartis. AH acted as a consultant for Novartis, BMS, Pfizer and Ariad, and received honoraria and research funding from Novartis, BMS and Pfizer. TPH acted as a consultant and received research funding from Novartis, BMS and Ariad. GS acted as a consultant for Novartis, BMS and Pfizer and received honoraria from BMS and Novartis. JPR acted as a consultant for Novartis, BMS, Ariad and Pfizer and received research funding from Novartis. D-WK received honoraria from Novartis and BMS and received research funding from Novartis, BMS, Pfizer and Ariad. GM acted as a consultant for Novartis, BMS, Pfizer and Genzyme, and received honoraria from Novartis and BMS; and research funding from Novartis. JR and RCW are Novartis employees and stock owners. MB acted as a consultant for Novartis, BMS and Pfizer, and received honoraria from Novartis, BMS and Pfizer, and received research funding from Novartis. HMK acted as a consultant for Novartis and received research funding from Novartis, BMS and Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}